XC001 is designed to transiently grow new blood vessels to restore blood flow in the heart. It contains alternative splicing of the three isoforms of VEGF-A, which sets it apart from past attempts at ...

We don't really understand how this would work on angina. Rasha Al-Lamee Tommaso Gori, MD (University Medical Center, Mainz, Germany), who wasn’t involved in the study, said that while ORBITA-COSMIC ...

ATLANTA -- For people with stable coronary artery disease and refractory angina, a coronary sinus reducer (CSR) implant ...

Newsweek is partnering with Statista for the inaugural ranking of the World's Best Digital Health Companies. The list ...

Feasibility study of an objective randomized blinded investigation of therapeutic ablation versus cardioversion for persistent Atrial Fibrillation (ORBITA-AF). Trial objective: Feasibility study of an ...

Alejandro Otero was traveling overseas when he received a panicked call from his son back home. An object tumbling from the ...

Experts And Viewpoints, November 15, 2023 AHA 2023 ORBITA-2 Saves Interventional Cardiology, Questions Guidance The second sham-controlled trial of PCI in stable CAD brings relief to the field but ...

Find out what's up in your night sky during May 2024 and how to see it in this Space.com stargazing guide. Looking for a telescope for the next night sky event? We recommend the Celestron Astro Fi ...

Findings from the ORBITA-COSMIC trial show that treatment of patients with stable coronary artery disease using a coronary sinus reducer improves angina symptoms but does not increase transmural ...

People with chronic chest pain who received a coronary sinus reducer (CSR)—a stent thought to increase the amount of oxygen-rich blood flowing to the heart muscle—experienced significant ...

The 'special and important' PUMA ORBITA ball helped score more than 200 goals in just over a week as part of a LGBTQ+ History ...

The ORBITA-COSMIC study manuscript was published simultaneously in The Lancet. This is an "important" trial as the refractory angina patient population is "incredibly challenging," said ACC ...